DXR Share Price | Daxor Corp. Stock Analysis & Recommendation

Q: How big is Daxor Corp.?

Market Cap: As of Jun 18, Daxor Corp. has a market capitalization of 43.53 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Daxor Corp. reported net sales of 1.45 million and a net profit of -7.18 million.Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 35.79 million and total assets of 36.63 million.

Q: What does Daxor Corp. do?

Overview: Daxor Corporation is an investment company engaged in medical instrumentation and biotechnology, focusing on the development of the Blood Volume Analyzer (BVA) -100 within the Capital Markets industry.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Dec 2011) Most recent Net Profit: -1 Million (Quarterly Results - Dec 2011) Market-cap: USD 43.53 Million (Micro Cap)Key Metrics: P/E: 32.00 Dividend Yield: 0.00% Debt Equity: -0.03 Return on Equity: 3.68% Price to Book: 1.22Contact Details: Address: 350 5th Ave Ste 4740, NEW YORK NY: 10118-0002 Tel: ['1 212 3308500', '1 212 3308512'] Fax: 1 212 2440806 Website: http://www.daxor.com/

Q: Is Daxor Corp. technically bullish or bearish?

As of 7 July 2025, the technical trend for Daxor Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are both bullish, supporting a positive outlook. The daily moving averages also indicate a bullish stance. While the Bollinger Bands show a mildly bullish trend on the weekly chart and bullish on the monthly, the KST is bullish weekly and mildly bullish monthly. The Dow Theory indicates a mildly bullish stance on the monthly timeframe, but there is no trend on the weekly. The RSI shows no signal for both weekly and monthly periods, and the OBV has no trend in either timeframe. There is no available return data for comparison with the S&P 500. Overall, the current technical stance is bullish with moderate strength.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.33 k

Shareholding (Dec 2024)

FII

0.06%

Held by 1 FIIs

DII

98.93%

Held by 1 DIIs

Promoter

0.00%

How big is Daxor Corp.?

22-Jun-2025

As of Jun 18, Daxor Corp. has a market capitalization of 43.53 million, with net sales of 1.45 million and a net profit of -7.18 million over the last four quarters. The company has shareholder's funds of 35.79 million and total assets of 36.63 million as of Dec 24.

View full answer

What does Daxor Corp. do?

22-Jun-2025

Daxor Corporation is an investment company specializing in medical instrumentation and biotechnology, primarily focused on developing the Blood Volume Analyzer (BVA) -100. As of December 2011, it reported net sales of $0 million and a net profit of -$1 million, with a market cap of $43.53 million.

View full answer

Who are in the management team of Daxor Corp.?

22-Jun-2025

As of March 2022, the management team of Daxor Corp. includes Mr. Michael Feldschuh (Chairman, President, CEO), Mr. Jonathan Feldschuh (Chief Scientific Officer), and several directors: Henry Cremisi, Edward Feuer, Joy Goudie, James Lombard, and Robert Willens.

View full answer

Is Daxor Corp. technically bullish or bearish?

20-Sep-2025

As of July 7, 2025, Daxor Corp. has a bullish technical trend supported by positive MACD indicators and daily moving averages, despite mixed signals from Bollinger Bands and no clear trends in RSI or OBV.

View full answer

Compare Daxor Corp. with Similar Stocks

Eargo, Inc.ReWalk Robotics Ltd.DermTech, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Capital Markets

Market cap

USD 68 Million ()

P/E

32.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

3.69%

Price to Book

1.91

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2011)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.97%

6 Months

-20.39%

1 Year

29.32%

2 Years

64.56%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Daxor Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.54%

EBIT Growth (5y)

EBIT to Interest (avg)

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.06

Tax Ratio

61.87%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

2.20%

ROCE (avg)

ROE (avg)

17.94%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.19

EV to EBIT

EV to EBITDA

42.66

EV to Capital Employed

1.19

EV to Sales

29.50

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

3.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 1 Schemes (1.01%)

Foreign Institutions

Held by 1 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Daxor Corp."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.29% vs 8,750.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 66.67% vs -94.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "-0.10",
          "val2": "34.60",
          "chgp": "-100.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.60",
          "val2": "0.30",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.50",
          "val2": "0.30",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "9.50%",
          "chgp": "-0.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

-0.10

34.60

-100.29%

Operating Profit (PBDIT) excl Other Income

0.60

0.30

100.00%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

0.50

0.30

66.67%

Operating Profit Margin (Excl OI)

0.00%

9.50%

-0.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.29% vs 8,750.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 66.67% vs -94.23% in Dec 2023

All Annual Results

Company CV

About Daxor Corp.

Daxor Corp.

Capital Markets

Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company focuses on the development of the Blood Volume Analyzer (BVA) -100, an instrument that rapidly and accurately measures human blood volume. The Company’s instrument is used in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.The Company also owns the Daxor Oak Ridge Operations (DORO) facility in Oak Ridge, Tennessee. The semi-automated BVA provides blood volume measurements in human body for diagnosis and treatment in a range of medical and surgical conditions.

Company Coordinates

Company Details

350 5th Ave Ste 4740 , NEW YORK NY : 10118-0002

Tel: 1 212 33085001 212 3308512

http://www.daxor.com/

Registrar Details

Daxor Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Daxor Corp.?

Watch in Real-Time

What does Daxor Corp. do?

Who are in the management team of Daxor Corp.?

Is Daxor Corp. technically bullish or bearish?

Compare Daxor Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Annual Results Snapshot (Consolidated) - Dec'24

About Daxor Corp.

Company Coordinates